查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585674

生物相似药市场：按产品、适应症、製造分类 - 2025-2030 年全球预测

Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

据预测，2023年生物相似药市场价值为407亿美元，预计2024年将达到499.1亿美元，复合年增长率为23.31%，到2030年将达到1764.8亿美元。

生物相似药是与已批准的参考产品高度相似的生物製药，有潜力为昂贵的生物製药提供具有成本效益的替代品，因此製药业已成为生物製品的重要组成部分。对生物相似药的需求源于医疗保健成本的上升和原始生物製药的专利到期，以及对治疗癌症、糖尿病和自体免疫疾病等慢性疾病的负担得起的治疗方法的需求。其应用涵盖肿瘤学、免疫学和内分泌学等各个治疗领域，最终用户范围延伸至医院、诊所和研究机构。市场成长受到慢性病盛行率上升、监管支持以及医疗保健提供者对生物相似药的接受程度提高等因素的显着影响。此外，新兴市场和製造流程的技术进步带来了巨大的商机。为了普及和扩大生物相似药市场，公司应专注于与医疗保健提供者的策略联盟和积极的营销策略。然而，挑战仍然存在，包括严格的监管要求、智慧财产权的复杂性以及需要进行大规模临床试验来证明与参考生技药品的相似性。另一个限制是不愿开立生物相似药，因为与原厂生技药品相比，人们仍然担心其有效性和安全性。儘管有这些障碍，该领域仍有丰富的创新途径，包括改善生物相似药开发流程、加强药物安全检测系统和优化供应链效率等。公司应该投资于改善相容性生物相似药配方的研究，这将能够在药房层面实现自动替代并提高市场渗透率。由于专利到期和研发投入高，生物相似药市场的特点是竞争激烈，需要持续创新和适应性行销才能满足全球对生物製药。

主要市场统计
基准年[2023] 407亿美元
预测年份 [2024] 499.1亿美元
预测年份 [2030] 1764.8亿美元
复合年增长率（%） 23.31%

市场动态：揭示快速发展的生物相似药市场的关键市场洞察

供需的动态相互作用正在改变生物相似药市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 製药业医疗保健支出增加
    • 对成本低于原厂生技药品的生物相似药的需求不断增加
  • 市场限制因素
    • 医生不愿意开立生物相似药
  • 市场机会
    • 改进生物相似药製造工艺
    • 政府对生物相似药开发的支持措施
  • 市场挑战
    • 严格的监管要求和法律

波特五力：驾驭生物相似药市场的策略工具

波特的五力架构是了解生物相似药市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解生物相似药市场的外部影响

外部宏观环境因素在塑造生物相似药市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生物相似药市场的竞争状况

对生物相似药市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生物相似药市场供应商绩效评估

FPNV定位矩阵是评估生物相似药市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了生物相似药市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，生物相似药市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 製药业医疗保健支出增加
      • 对成本低于原始生物製药的生物相似药的需求增加
    • 抑制因素
      • 医生不愿意开立生物相似药
    • 机会
      • 改进生物相似药製造工艺
      • 政府支持生物相似药开发的倡议
    • 任务
      • 严格的监管要求和法律
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生物相似药市场：副产品

  • 重组糖化蛋白
    • 促红血球生成素
    • 促滤泡素
    • 单株抗体
      • Adalimumab
      • Infliximab
      • Rituximab
  • 重组非糖基化蛋白
    • 颗粒细胞增生因子
    • 胰岛素
    • 干扰素
      • α干扰素
      • β型干扰素
    • 重组人体生长荷尔蒙
  • 重组胜胜肽
    • 抑钙素
    • 升糖素

第七章依适应症分類的生物相似药市场

  • 自体免疫疾病
  • 血液疾病
  • 慢性疾病
  • 生长激素缺乏症
  • 感染疾病
  • 肿瘤学

第八章 生物相似药市场製造业

  • 契约製造
  • 内部製造

第九章美洲生物相似药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太生物相似药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的生物相似药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck & Co., Inc.
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-4358917D6590

The Biosimilars Market was valued at USD 40.70 billion in 2023, expected to reach USD 49.91 billion in 2024, and is projected to grow at a CAGR of 23.31%, to USD 176.48 billion by 2030.

Biosimilars, biologic medical products highly similar to already authorized reference products, represent a key segment within the pharmaceutical industry due to their potential to offer cost-effective alternatives to expensive biologics. The necessity for biosimilars arises from increasing healthcare costs and patent expirations of original biologics, driving demand for affordable therapies in treating chronic diseases like cancer, diabetes, and autoimmune disorders. Their applications span across various therapeutic areas, including oncology, immunology, and endocrinology, with end-user scope extending to hospitals, clinics, and research institutes. Market growth is heavily influenced by factors such as rising incidences of chronic diseases, regulatory support, and healthcare providers' growing acceptance of biosimilars. Moreover, emerging markets and technological advancements in manufacturing processes present substantial opportunities. Businesses should focus on strategic collaborations with healthcare providers and aggressive marketing strategies to enhance biosimilar adoption and expand market reach. However, challenges persist, including stringent regulatory requirements, intellectual property complexities, and the need for extensive clinical trials to establish similarity to reference biologics. Another limitation is the hesitancy in prescribing biosimilars due to lingering concerns regarding efficacy and safety compared to original biologics. Despite these hurdles, the sector holds rich avenues for innovation, particularly in improving biosimilar development processes, enhancing pharmacovigilance systems, and optimizing supply chain efficiencies. Companies should invest in research focused on improving interchangeable biosimilar formulations, which can lead to automatic substitution at the pharmacy level, thereby increasing market penetration. The biosimilars market is characterized by intense competition driven by patent expirations and high research and development investments, suggesting that staying ahead necessitates continuous innovation and adaptive marketing strategies to capitalize on burgeoning global demand for biologic treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 40.70 billion
Estimated Year [2024] USD 49.91 billion
Forecast Year [2030] USD 176.48 billion
CAGR (%) 23.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimilars Market

The Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure into the pharmaceutical industry
    • Increasing demand for lower cost biosimilars drugs than original biologics
  • Market Restraints
    • Reluctance of physicians to prescribe biosimilars
  • Market Opportunities
    • Improvements in biosimilar production processes
    • Supportive government initiative to develop biosimilars
  • Market Challenges
    • Stringent regulatory requirements and laws

Porter's Five Forces: A Strategic Tool for Navigating the Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimilars Market

A detailed market share analysis in the Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimilars Market

A strategic analysis of the Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.
  • Based on Indication, market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
  • Based on Manufacturing, market is studied across Contract Manufacturing and In-House Manufacturing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
      • 5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Reluctance of physicians to prescribe biosimilars
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in biosimilar production processes
      • 5.1.3.2. Supportive government initiative to develop biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and laws
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimilars Market, by Product

  • 6.1. Introduction
  • 6.2. Recombinant Glycosylated Proteins
    • 6.2.1. Erythropoietin
    • 6.2.2. Follitropin
    • 6.2.3. Monoclonal Antibodies
      • 6.2.3.1. Adalimumab
      • 6.2.3.2. Infliximab
      • 6.2.3.3. Rituximab
  • 6.3. Recombinant Non-Glycosylated Proteins
    • 6.3.1. Granulocyte Colony-Stimulating Factor
    • 6.3.2. Insulin
    • 6.3.3. Interferons
      • 6.3.3.1. Interferon-Alpha
      • 6.3.3.2. Interferon-Beta
    • 6.3.4. Recombinant Human Growth Hormone
  • 6.4. Recombinant Peptides
    • 6.4.1. Calcitonin
    • 6.4.2. Glucagon

7. Biosimilars Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Blood Disorders
  • 7.4. Chronic Diseases
  • 7.5. Growth Hormone Deficiency
  • 7.6. Infectious Diseases
  • 7.7. Oncology

8. Biosimilars Market, by Manufacturing

  • 8.1. Introduction
  • 8.2. Contract Manufacturing
  • 8.3. In-House Manufacturing

9. Americas Biosimilars Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Biosimilars Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvotech
  • 2. Amgen Inc.
  • 3. Apotex Inc.
  • 4. Biocon Limited
  • 5. BioFactura, Inc.
  • 6. Biogen Inc.
  • 7. Boehringer Ingelheim International GmbH.
  • 8. Catalent, Inc
  • 9. Celltrion Healthcare Co.,Ltd.
  • 10. Coherus BioSciences
  • 11. Dr. Reddy's Laboratories Limited
  • 12. Eden Biologics, Inc.
  • 13. F. Hoffmann-La Roche AG
  • 14. Fresenius Kabi
  • 15. Innovent Biologics, Inc.
  • 16. Intas Pharmaceuticals Ltd.
  • 17. Kashiv BioSciences, LLC.
  • 18. Merck & Co., Inc.
  • 19. NeuClone
  • 20. Nippon Kayaku Co., Ltd.
  • 21. Novartis AG
  • 22. Panacea Biotec Limited
  • 23. Pfizer Inc.
  • 24. Samsung Bioepis Co., Ltd.
  • 25. Sanofi S.A.
  • 26. Shanghai Henlius Biotech, Inc.
  • 27. Teva Pharmaceutical Industries Ltd.
  • 28. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMILARS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)

TABLE 354